Executive Scientific Committee

Members

	Dr M. BALTAS (CNRS, University of Toulouse, Toulouse, France)
	Prof. R. BUREAU (University of Caen, Caen, France)
	Prof. P. DALLEMAGNE (University of Caen, Caen, France)
	Dr P. GEORGE (SCT & Independent Scientific Expert & Adviser, Longvilliers, France)
	Prof. B. LINCLAU (University of Southampton, Southampton, United Kingdom)
	Prof. C. ROCHAIS (University of Caen, Caen, France)
	Prof. J. SAPI (SCT & University of Reims-Champagne-Ardenne, Reims, France)
	Dr L. VAN HIJFTE (SCT & NovAliX, Illkirch, France)
	Prof. A. S. VOISIN-CHIRET (University of Caen, Caen, France)

Local Organising Committee

Members

	Prof. R. BUREAU (University of Caen, Caen, France)
	Prof. V. COLLOT (University of Caen, Caen, France)
	Prof. P. DALLEMAGNE (University of Caen, Caen, France)
	Prof. F. FABIS (University of Caen, Caen, France)
	Prof. A. MALZERT-FREON (Unversity of Caen, Caen, France)
	Prof. C. ROCHAIS (University of Caen, Caen, France)
	Prof. A. S. VOISIN-CHIRET (University of Caen, Caen, France)

Scientific Advisory Board

Members

	Dr F. ACHER (CNRS - University Paris Descartes, Paris, France)
	Dr K.-H. BARINGHAUS (SANOFI-AVENTIS, Frankfurt am Main, Germany)
	Prof. J. BOCKAERT (University of Montpellier, Montpellier, France)
	Prof. M. L. BOLOGNESI (University of Bologna, Bologna, Italy)
	Prof. P. BONNET (University of Orléans, Orléans, France)
	Dr A. BROWN (Stratified Medical, London, United Kingdom)
	Dr M. CASES-THOMAS (Eli Lilly & Company, Windlesham, United Kingdom)
	Mr J.-D. CHARRIER (Vertex Pharmaceuticals, OXON, United Kingdom)
	Dr J. CHRISTOPHER (Heptares, Hertfordshire, United Kingdom)
	Dr I. DORANGE (DOMAIN THERAPEUTICS, ILLKIRCH, France)
	Dr C. GARCIA-ECHEVERRIA (Sanofi, Vitry sur Seine, France)
	Dr J. GRACIA (Almirall, Barcelona, Spain)
	Prof. Y. HASHIMOTO (The University of Tokyo, Tokyo, Japan)
	Prof. J. HASSERODT (ENS, Lyon, France)
	Prof. M. HIBERT (Université de Strasbourg, Illkirch, France)
	Dr L. LINUS (Eli Lilly & Company, Shanghai, China)
	Dr G. J. MACDONALD (Janssen Research & Development, Beerse, Belgium)
	Dr F. MARSAIS (VFP Therapies, Rouen, France)
	Dr D. MEIBOM (Bayer Pharma, Wuppertal, Germany)
	Dr C. MENET (Confo Therapeutics, Brussels, Belgium)
	Dr A. T. PLOWRIGHT (AstraZeneca, Mölndal, Sweden)
	Dr R. PRUSS (Trophos SA, Marseille Cedex 9, France)
	Prof. J.-L. REYMOND (SCS DMCCB & University of Bern, Bern, Switzerland)
	Dr J.-P. ROCHER (Pierre Fabre Research Institute, Toulouse, France)
	Dr H. UENO (Mitsubishi Tanabe Pharma, Osaka , Japan)
	Prof. M. UESUGI (Kyoto University, Kyoto, Japan)
	Dr A. VALADE (UCB, Braine-l'Alleud, Belgium)
	Dr J. VELCICKY (Novartis Institutes for Biomedical Research, Basel, Switzerland)
	Dr F. VON NUSSBAUM (Bayer Pharma, Lyon, France)
	Dr J. WAI (WuXi AppTec, Shanghai, China)
	Prof. M. WARING (University of Newcastle, Newcastle upon Tyne, United Kingdom)